Suzetrigine and the Promise of Non-Opioid Pain Relief. At the forefront of Vertex's expansion into pain management is suzetrigine (VX-548), a novel drug candidate with the potential to ...

A non-opioid pain medication made by Vertex Pharmaceuticals has received approval for adults from the Food and Drug Administration (FDA). The company’s "first-in-class" suzetrigine pain pill ...

Vertex's stock has risen 18% since last December, ... to believe VK-548's potential in neuropathies is more interesting than its potential in a crowded and complex acute pain management market.

Acute pain is something more than 80 million Americans fill prescriptions to treat each year, according to Vertex. As opposed to chronic pain, which can last well after an injury or illness has ...

Vertex Pharmaceuticals (VRTX – Research Report), the Healthcare sector company, ... A Promising Non-Opioid Solution to Acute Pain Management. TipRanks. Oct. 21, 2024, 04:55 AM.

Vertex's candidate, called VX-548, targets NaV1.8 sodium channels, which are thought to play a role in relaying pain signals to the spinal cord from peripheral nerves.

When faced with the myriad diseases and equally numerous targets for potential drugs the company could pursue, Kewalramani ...

If Vertex does get payer buy-in, Journavx could be an exception to a longstanding, unwritten rule in pain management: fresh therapies take a while to reach patients.

Leerink Partners analyst David Risinger maintained a Buy rating on Vertex Pharmaceuticals (VRTX – Research Report) yesterday and set a price target of $600.00. David Risinger has given his Buy ...

Vertex is strategically expanding into the pain management sector, Vertex Pharmaceuticals (NASDAQ:VRTX) is a biotechnology company with a strong track record of success in developing treatments ...